Lantheus Holdings Inc
Company Profile
Business description
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Contact
201 Burlington Road
South Building
BedfordMA01730
USAT: +1 978 671-8001
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,193
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
stocks
Lower moat ratings on four ASX shares due to AI
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,733.70 | 106.80 | -1.21% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,135.35 | 621.94 | -2.41% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 51,740.46 | 3,880.38 | -6.98% |
| NZX 50 Index | 13,087.37 | 530.52 | -3.90% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,509.80 | 92.50 | -1.08% |
| SSE Composite Index | 4,081.89 | 42.30 | -1.03% |